We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Joining a host of other drug companies announcing slim-down efforts in recent months, Astellas is shedding 600 positions in Japan in R&D and sales and marketing.